Regeneron’s highly-anticipated coronavirus antibody drug faced a setback Friday when an outside panel recommended its trial of the antibody cocktail to treat severely-ill COVID-19 patients be paused over a ‘potential safety concern.’ Trials for the antibody cocktail – the same experimental treatment given to President Trump shortly after he tested positive for COVID-19 earlier this...
